Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Gastrointestinal and Other Cancers
Sponsor
National Cancer Institute (NCI)
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02968810
This phase II trial studies how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Intervention
Questionnaire Administration, Simvastatin, Placebo Administration, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Condition
Cirrhosis, Hepatocellular Carcinoma
Investigators
Marc T Goodman